frontotemporal lobar degeneration

frontotemporal lobar degeneration
Name	Frontotemporal lobar degeneration
Field	Neurology, Neuropathology
Onset	Typically 45–65 years
Causes	Neurodegeneration, protein aggregation
Prognosis	Progressive; variable survival

Contents

frontotemporal lobar degeneration

Frontotemporal lobar degeneration is a group of neurodegenerative disorders characterized by progressive degeneration of the frontal and temporal lobes, leading to changes in behavior, language, and executive function. First described in clinical series associated with institutions such as University of Pennsylvania Hospital and research centers including Mayo Clinic and Massachusetts General Hospital, the syndrome has been studied by investigators at University College London, University of California, San Francisco, and Karolinska Institutet. Clinical investigation has involved consortia such as the Alzheimer's Disease Neuroimaging Initiative and collaborations with neuropathology groups at the National Institutes of Health.

Signs and symptoms

Patients often present with disinhibition, apathy, loss of empathy, compulsive behaviors, or language deficits noted by clinicians at centers like Johns Hopkins Hospital and Cleveland Clinic. Behavioral changes may prompt evaluation by psychiatrists affiliated with McLean Hospital or Bellevue Hospital, with caregivers reporting altered social conduct in contexts involving figures such as Queen Elizabeth II, Nelson Mandela, or public incidents covered by media outlets like BBC News, The New York Times, and The Washington Post. Progressive aphasia syndromes produce anomia, agrammatism, or semantic impairment observed in clinics associated with Stanford University, Columbia University, and University of Toronto. Motor neuron disease features overlapping with this condition have been documented in studies at Imperial College London and University of Tokyo, linking to presentations similar to those described in cohorts from University of Sydney and Monash University.

Pathological subtypes are defined by protein inclusions identified by neuropathologists at institutions including Cambridge University Hospitals, University of Edinburgh, and Charité – Universitätsmedizin Berlin. Abnormal accumulations of tau, TDP-43, and fused in sarcoma protein have been characterized in laboratories at Rockefeller University, Salk Institute, and Institut Pasteur. Immunohistochemical techniques developed in groups led by researchers at Max Planck Institute for Brain Research and Broad Institute differentiate tauopathies from TDP-43 proteinopathies and FUS-related cases, paralleling work on prion disorders at University of Cambridge. Regional atrophy patterns correlate with findings from imaging centers like Karolinska University Hospital and Hospital Clinic de Barcelona.

Familial cases have been linked to pathogenic variants in genes such as MAPT, GRN, and C9orf72 identified by geneticists at University of Antwerp, University of Glasgow, and University of Helsinki. Epidemiological risk studies have been conducted by groups at Duke University, University of California, Los Angeles, and University of Melbourne, noting associations with middle-age onset and positive family history recorded in cohorts from Framingham Heart Study-related collaborations. Environmental and occupational investigations involving exposure frameworks used by World Health Organization and Centers for Disease Control and Prevention remain inconclusive, while population registries curated by Swedish National Board of Health and Welfare and Scotland's NHS contribute incidence data.

Diagnosis relies on clinical assessment, neuropsychological testing, and neuroimaging performed at centers such as Mayo Clinic, Massachusetts General Hospital, and Mount Sinai Hospital. Structural MRI and FDG-PET studies used in protocols developed at Harvard Medical School and Yale School of Medicine demonstrate frontotemporal atrophy and hypometabolism, respectively, paralleling biomarker work from Karolinska Institutet and University of Oxford. Genetic testing follows recommendations from organizations like American College of Medical Genetics and Genomics and diagnostic criteria advanced by research consortia including International Behavioural Variant FTD Criteria Consortium and groups at University College London.

The classification includes behavioral variant, nonfluent/agrammatic primary progressive aphasia, and semantic variant primary progressive aphasia as described in consensus statements from National Institute on Aging and Alzheimer's Association, and elaborated by research teams at University of Pennsylvania, University of Cambridge, and University of California, San Diego. Overlap with amyotrophic lateral sclerosis has been documented in collaborations between Institut National de la Santé et de la Recherche Médicale and University of Cologne. Pathological nomenclature distinguishes FTLD-tau, FTLD-TDP, and FTLD-FUS based on neuropathology reports from MRC Laboratory of Molecular Biology and Mount Sinai School of Medicine.

Management is multidisciplinary, involving neurologists and allied health teams at institutions like Guy's and St Thomas' NHS Foundation Trust, Royal Melbourne Hospital, and Vanderbilt University Medical Center. Symptomatic treatments draw on pharmacologic strategies used in centers such as Massachusetts General Hospital and Mayo Clinic, while behavioral interventions are guided by neurorehabilitation programs at Kennedy Krieger Institute and Spaulding Rehabilitation Hospital. Genetic counseling is provided following models from Genetics Home Reference and clinics at St. Jude Children's Research Hospital. Prognosis varies; survival ranges reported in cohorts from University of California, San Francisco and University of Toronto reflect heterogeneity in onset, variant, and comorbidities captured in registries maintained by European Alzheimer’s Disease Consortium and Global Brain Health Institute.